Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab Vedotin in Aggressive Thyroid Cancers and NUT Carcinoma
NCT07863765Phase 2Not yet recruiting
- Sponsor
- Northwestern University
- Start
- May 2027
- Primary completion
- May 2030
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin in differentiated thyroid cancer (DTC), anaplastic thyroid cancer (ATC), Medullary Thyroid Cancer (MTC), NUT carcinoma (NC), sponsored by Northwestern University. Planned start May 2027; status: not yet recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
differentiated thyroid cancer (DTC)anaplastic thyroid cancer (ATC)Medullary Thyroid Cancer (MTC)NUT carcinoma (NC)
Beyond the preview
Go deeper on NCT07863765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07863765.